Gallbladder Neoplasms
12
2
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.4% vs benchmark
17%
2 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (12)
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Agnostic Therapy in Rare Solid Tumors
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Selective Rather Than Routine Histopathological Examination Following Appendectomy and Cholecystectomy
Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer
EEG Parameters Between Remimazolam- and Propofol-based Anesthesia
Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms
Chinese Research Group of Gallbladder Cancer
ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma